Figure 1. Lysm+FBXW7f/f mice show aggravated tumor progression in an LLC-inoculated model. (A) LLCs were subcutaneously injected into the mice. The volume of tumors from FBXW7f/f and Lysm+FBXW7f/f mice were measured and recorded in 16 days (n = 5 per group). (B) The weight of tumors at 16 days from both groups (n = 5 per group). (C) The appearance of tumors dissected 16 days after inoculation in FBXW7f/f and Lysm+FBXW7f/f mice. (D) The survival curve of tumor-bearing FBXW7f/f and Lysm+FBXW7f/f mice (n = 10 per group). (E) Representative images of tumors from two groups immunohistochemically stained with an antibody against Ki67. Scale bars: 10× was 200 μm, 40× was 50 μm. Data are expressed as the mean ± SD and are representative of three independent experiments. *P < 0.05; **P < 0.01; ****P < 0.0001 (two-way ANOVA (A), Student’s t test (B) and log rank test (D)).